The stock of Lyell Immunopharma Inc (LYEL) has gone down by -7.79% for the week, with a -26.78% drop in the past month and a -25.49% drop in the past quarter. The volatility ratio for the week is 12.24%, and the volatility levels for the past 30 days are 12.06% for LYEL. The simple moving average for the past 20 days is -18.42% for LYEL’s stock, with a -55.23% simple moving average for the past 200 days.
Is It Worth Investing in Lyell Immunopharma Inc (NASDAQ: LYEL) Right Now?
Company’s 36-month beta value is -0.27.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for LYEL is 124.87M, and currently, short sellers hold a 4.79% ratio of that floaft. The average trading volume of LYEL on April 02, 2025 was 1.03M shares.
LYEL) stock’s latest price update
The stock of Lyell Immunopharma Inc (NASDAQ: LYEL) has decreased by -9.98 when compared to last closing price of 0.54.Despite this, the company has seen a loss of -7.79% in its stock price over the last five trading days. globenewswire.com reported 2025-03-11 that SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2024.
Analysts’ Opinion of LYEL
Many brokerage firms have already submitted their reports for LYEL stocks, with BofA Securities repeating the rating for LYEL by listing it as a “Underperform.” The predicted price for LYEL in the upcoming period, according to BofA Securities is $1 based on the research report published on October 30, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYEL reach a price target of $1, previously predicting the price at $6. The rating they have provided for LYEL stocks is “Neutral” according to the report published on June 27th, 2024.
JP Morgan gave a rating of “Neutral” to LYEL, setting the target price at $5 in the report published on August 28th of the previous year.
LYEL Trading at -20.34% from the 50-Day Moving Average
After a stumble in the market that brought LYEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.60% of loss for the given period.
Volatility was left at 12.06%, however, over the last 30 days, the volatility rate increased by 12.24%, as shares sank -31.17% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.85% lower at present.
During the last 5 trading sessions, LYEL fell by -7.79%, which changed the moving average for the period of 200-days by -81.08% in comparison to the 20-day moving average, which settled at $0.5937. In addition, Lyell Immunopharma Inc saw -24.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LYEL starting from Ramachandra Sumant, who purchase 200,000 shares at the price of $0.58 back on Mar 21 ’25. After this action, Ramachandra Sumant now owns 200,000 shares of Lyell Immunopharma Inc, valued at $115,220 using the latest closing price.
Klausner Richard, the Director of Lyell Immunopharma Inc, purchase 158,000 shares at $0.60 during a trade that took place back on Mar 14 ’25, which means that Klausner Richard is holding 843,365 shares at $94,942 based on the most recent closing price.
Stock Fundamentals for LYEL
Current profitability levels for the company are sitting at:
- -5919.49 for the present operating margin
- -161.7 for the gross margin
The net margin for Lyell Immunopharma Inc stands at -5622.85. The total capital return value is set at -0.83. Equity return is now at value -66.10, with -55.28 for asset returns.
Based on Lyell Immunopharma Inc (LYEL), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -2.75.
Currently, EBITDA for the company is -3.31 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 1579.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.06.
Conclusion
In a nutshell, Lyell Immunopharma Inc (LYEL) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
